Announcements Trials
Browse Landscape

Phase

Phase NA 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Esophageal Neoplasms 3Stomach Neoplasms 2Glioma 2Warts 1Uveal Melanoma 1Uterine Cervical Neoplasms 1Radiation Injuries 1Oligodendroglioma 1Melanoma 1Lung Neoplasms 1Esophagitis 1Cardiovascular Diseases 1Cardiotoxicity 1Carcinoma, Non-Small-Cell Lung 1Breast Neoplasms 1Astrocytoma 1

Interventions

Trastuzumab 597Paclitaxel 562Cyclophosphamide 545Docetaxel 479Capecitabine 388Letrozole 350Fulvestrant 311Doxorubicin 285Carboplatin 277Tamoxifen 257Anastrozole 219exemestane 211Epirubicin 210Radiotherapy 197Bevacizumab 189pertuzumab 177Gemcitabine 163Vinorelbine 162pembrolizumab 161Lapatinib 161palbociclib 152Exercise 132Fluorouracil 118Albumin-Bound Paclitaxel 116eribulin 108Magnetic Resonance Spectroscopy 108130-nm albumin-bound paclitaxel 107Everolimus 103Taxes 96Cisplatin 92

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Breast Neoplasms × Heart Rate × Clear all
NCT04568161 2025-04-03

Effect of Anthracyclines and Cyclophosphamide on Cardiovascular Responses

University of Sao Paulo General Hospital

Phase NA Completed
15 enrolled
Breast

Breast Neoplasms, Cardiovascular Diseases, Cardiotoxicity

Data powered by HemOnc (CC BY 4.0) Colophon âš¡